Edwards Lifesciences Corp

For the period ended Mar 31, 2026. Filed May 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 6, 2026

EW$104.01-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 1. Financial Statements (Unaudited)

Item 1. Financial Statements

CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, except par value; unaudited)

	March 31,2026	December 31,2025
ASSETS
Current assets
Cash and cash equivalents	$2,445.5	$2,938.0
Short-term investments (Note 5)	1,226.0	1,288.3
Accounts receivable, net of allowances of $15.6 and $15.0, respectively	775.7	659.6
Other receivables	197.3	252.5
Inventories (Note 2)	1,119.0	1,126.2
Prepaid expenses	135.7	135.0
Other current assets	329.5	339.3
Total current assets	6,228.7	6,738.9
Long-term investments (Note 5)	285.6	278.6
Property, plant, and equipment, net	1,823.1	1,811.9
Operating lease right-of-use assets	99.3	102.7
Goodwill	1,819.6	1,768.6
Other intangible assets, net	1,227.9	1,128.2
Deferred income taxes	1,098.1	1,138.1
Other assets (Note 2)	738.9	730.2
Total assets	$13,321.2	$13,697.2
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable	$181.1	$227.5
Accrued and other liabilities (Note 2)	1,203.6	1,561.7
Operating lease liabilities	24.3	24.5
Total current liabilities	1,409.0	1,813.7
Long-term debt	598.5	598.3
Operating lease liabilities	80.1	82.6
Uncertain tax positions	555.4	502.7
Other liabilities	350.7	362.3
Total liabilities	2,993.7	3,359.6
Commitments and contingencies (Note 12)
Stockholders' equity
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding	—	—
Common stock, $1.00 par value, 1,050.0 shares authorized, 660.0 and 658.7 shares issued, and 577.0 and 580.7 shares outstanding, respectively	660.0	658.7
Additional paid-in capital	2,781.5	2,768.4
Retained earnings	14,621.2	14,240.5
Accumulated other comprehensive loss (Note 13)	(221.3)	(238.3)
Treasury stock, at cost, 83.0 and 78.0 shares, respectively	(7,513.9)	(7,091.7)
Total Edwards Lifesciences Corporation stockholders' equity	10,327.5	10,337.6
Total liabilities and equity	$13,321.2	$13,697.2

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.